Jenner researchers at science pop-up event in Swindon
26 February 2025
In an age of rapid information (and misinformation), public engagement with science is more important than ever. Jenner Institute staff and PhD students talked about their work at an science pop up in Swindon during half term.
Head of trailblazing clinical research facility in Burkina Faso visits Oxford
23 January 2025
Professor Halidou Tinto visited the Jenner Institute and gave a seminar on the international partnerships for health research in Africa. He told the story of how he created the first clinical research facility in Burkina Faso. The renowned Clinical Research Unit of Nanoro plays a crucial role in the fight against malaria and his team led the phase I/IIb clinical trial for the R21/Matrix-M malaria vaccine developed at the Jenner Institute.
Côte d’Ivoire makes history as first nation to deploy R21/Matrix-M™ Malaria Vaccine
15 July 2024
Today marks the official rollout of the new R21/Matrix-M™ malaria vaccine - co-developed by the University of Oxford and Serum Institute of India, leveraging Novavax’s Matrix-M™ adjuvant technology. In a historic step in the battle to beat malaria, the first official vaccination is due to take place in Abidjan, Côte d’Ivoire, this morning and will be subsequently rolled-out in 38 districts across the country.
The Jenner Institute Early Researchers Symposium 2024
13 June 2024
On June 7, 2024, the second annual Jenner Institute Early Researchers Symposium (JERS) was held at St Anne's College, bringing together a vibrant community of over 80 DPhil Students, Research Assistants, Technicians and Apprentices from across the Nuffield Department of Medicine to network, share their research and discuss career aspirations.
Shipment of R21 malaria vaccine to Central African Republic marks latest milestone for child survival
6 June 2024
Last month, UNICEF delivered over 43,200 doses of the R21/Matrix-M malaria vaccine developed through collaboration between Oxford University’s Jenner Institute and Serum Institute of India leveraging by Novavax’s saponin-based adjuvant technology, by air to Bangui, Central African Republic, with further shipment of about 163,800 doses to follow, which is allocated for children in the CAR currently.
Jenner Institute director receives award for an Outstanding Contribution to Translational Medicine
27 May 2024
The Director of the Jenner Institute, Professor Sir Adrian Hill, was announced as the 2024 recipient of the UK Association of Physicians’ award for an Outstanding Contribution to Translational Medicine. He was presented with the award at a ceremony during the annual meeting held in Newcastle 23-24 May, 2024.
Public event: Tuberculosis - vaccines, diagnostics and experience
24 May 2024
On Wednesday 5th June, the University of Oxford is marking the 100th anniversary of the death of Franz Kafka, who died in 1924 of tuberculosis, with a programme of activities celebrating his works and enduring legacy. The event will include a talk by Prof Helen McShane, Head of the Jenner Institute TB Vaccine Programme.
Vice-Chancellor's Award for R21 Malaria vaccine team
8 May 2024
The R21/Matrix-M Malaria vaccine clinical development programme team from the Jenner Institute has won the Innovation and Commercialisation category of the University of Oxford Vice-Chancellor’s Awards 2024. The team, led by Prof. Sir Adrian Hill, is behind the clinical development of the R21 Malaria vaccine which is due to be rolled out in the first African countries in the next months. The Vice-Chancellor’s Awards recognise the achievements and celebrate success across the University.
FCDO Minister meets with Jenner Institute researchers
25 January 2024
Mr. Mitchell, along with Professor Charlotte Watts, FCDO Chief Scientific Adviser and Director for Research and Evidence, toured the research facilities of the Jenner Institute, the Oxford Vaccine Group and the Pandemic Sciences Institute, following the government announcement in Davos of an additional £10 million to support the effective roll-out of two new malaria vaccines both developed by British science.
Scientists receive the European Hector Research Award for HIV
3 November 2023
The AELIX-002 study group research was awarded the European Hector Research Award in HIV for research on the therapeutic vaccine against HIV. The researchers include Prof Tomáš Hanke, Professor of Vaccine Immunology at the Jenner Institute at NDM.
Oxford R21/Matrix-M™ malaria vaccine receives WHO recommendation for use paving the way for global roll-out
2 October 2023
The highly effective vaccine developed by the University of Oxford and the Serum Institute of India, leveraging Novavax’s adjuvant is critical to reducing over half a million malaria-related deaths annually.
Oxford R21/Matrix-M™ malaria vaccine receives regulatory clearance for use in Burkina Faso
24 July 2023
The University of Oxford-developed, Serum Institute of India PvT Ltd (SIIPL) manufactured and scaled up R21/Matrix-MTM malaria vaccine, leveraging Novavax’s adjuvant technology, has been licensed for use in Burkina Faso by the country’s regulatory agency, Agence Nationale de la Regulation Pharmaceutique (ANRP).
African Phase I HIV vaccine trial shows encouraging preliminary results
12 July 2023
The multisite Phase I HIV-CORE 006 HIV vaccine clinical trial, run by the Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT), has concluded successfully. Preliminary analysis of the immunological trial results demonstrates the induction of high frequencies of broadly specific T cells that recognise functionally conserved regions on HIV-1 and are therefore more protective.
Jenner Institute DPhil Symposium
6 July 2023
The Jenner Institute DPhil Symposium on 23 June 2023 brought together over 80 DPhil Students, Research Assistants, Technicians and Apprentices across the Nuffield Department of Medicine to network and share their research and career aspirations. The day was organised entirely by DPhil Students: Adam Khan-Qureshi, Marco Polo Peralta Alvarez, Rebecca Makinson, Samuel Provstgaard-Morys, Meera Madhavan, Christopher De Voss, and Adam Norton-Steele, with the support from Professor Katie Ewer, Assistant Director of Studies at the Jenner Institute.
R21/Matrix-M™ malaria vaccine developed by University of Oxford receives regulatory clearance for use in Ghana
13 April 2023
The University of Oxford-developed and Serum Institute of India PvT Ltd (SIIPL)- manufactured and scaled up R21/Matrix-MTM malaria vaccine, leveraging Novavax’s adjuvant technology, has been licensed for use in Ghana by the country’s Food and Drugs Authority.
Mexican Ambassador visits Jenner Institute
24 March 2023
The Mexican Ambassador to the United Kingdom, Her Excellency Ms Josefa González-Blanco Ortiz Mena, was given a tour and met with representatives of the Jenner Institute.
Romain Guyon awarded 2022 Michelson Prize
2 February 2023
DPhil student at the Jenner Institute, Romain Guyon is among the researchers who received the 2022 Michelson Prizes: Next Generation Grants, announced by Michelson Medical Research Foundation and Human Immunome Project.
Oxford gets £122m funding for healthcare research
14 October 2022
Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the city’s two NIHR Biomedical Research Centres (BRC). Professor Helen McShane, Director of the NIHR Oxford BRC and Jenner Investigator said: 'This funding is a recognition of the high calibre work done by our researchers in recent years'.